Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer.
See All Pages
Find People
Find Everything
Edit My Profile
My Person List (
0
)
Return to Top
Login
Username
Password